Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays - PubMed (original) (raw)
. 2011 Dec 15;17(24):7614-24.
doi: 10.1158/1078-0432.CCR-11-1536. Epub 2011 Oct 20.
Jeffrey A Ecsedy, Arijit Chakravarty, Lee Silverman, Mengkun Zhang, Kara M Hoar, Stephen G Stroud, Wei Chen, Vaishali Shinde, Jessica J Huck, Deborah R Wysong, David A Janowick, Marc L Hyer, Patrick J Leroy, Rachel E Gershman, Matthew D Silva, Melissa S Germanos, Joseph B Bolen, Christopher F Claiborne, Todd B Sells
Affiliations
- PMID: 22016509
- DOI: 10.1158/1078-0432.CCR-11-1536
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays
Mark G Manfredi et al. Clin Cancer Res. 2011.
Abstract
Purpose: Small-molecule inhibitors of Aurora A (AAK) and B (ABK) kinases, which play important roles in mitosis, are currently being pursued in oncology clinical trials. We developed three novel assays to quantitatively measure biomarkers of AAK inhibition in vivo. Here, we describe preclinical characterization of alisertib (MLN8237), a selective AAK inhibitor, incorporating these novel pharmacodynamic assays.
Experimental design: We investigated the selectivity of alisertib for AAK and ABK and studied the antitumor and antiproliferative activity of alisertib in vitro and in vivo. Novel assays were used to assess chromosome alignment and mitotic spindle bipolarity in human tumor xenografts using immunofluorescent detection of DNA and alpha-tubulin, respectively. In addition, 18F-3'-fluoro-3'-deoxy-l-thymidine positron emission tomography (FLT-PET) was used to noninvasively measure effects of alisertib on in vivo tumor cell proliferation.
Results: Alisertib inhibited AAK over ABK with a selectivity of more than 200-fold in cells and produced a dose-dependent decrease in bipolar and aligned chromosomes in the HCT-116 xenograft model, a phenotype consistent with AAK inhibition. Alisertib inhibited proliferation of human tumor cell lines in vitro and produced tumor growth inhibition in solid tumor xenograft models and regressions in in vivo lymphoma models. In addition, a dose of alisertib that caused tumor stasis, as measured by volume, resulted in a decrease in FLT uptake, suggesting that noninvasive imaging could provide value over traditional measurements of response.
Conclusions: Alisertib is a selective and potent inhibitor of AAK. The novel methods of measuring Aurora A pathway inhibition and application of tumor imaging described here may be valuable for clinical evaluation of small-molecule inhibitors.
©2011 AACR.
Similar articles
- Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S, Patel M, Huck J, Zhang M, Balani SK, Yang J, Chen S, Mettetal J, Manfredi M, Shyu WC, Ecsedy JA, Chakravarty A. Palani S, et al. Cancer Chemother Pharmacol. 2013 Dec;72(6):1255-64. doi: 10.1007/s00280-013-2305-8. Epub 2013 Oct 8. Cancer Chemother Pharmacol. 2013. PMID: 24101146 - Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V. Fuereder T, et al. Clin Cancer Res. 2011 Aug 15;17(16):5322-32. doi: 10.1158/1078-0432.CCR-10-1659. Epub 2011 Jun 28. Clin Cancer Res. 2011. PMID: 21712451 - Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J. Cervantes A, et al. Clin Cancer Res. 2012 Sep 1;18(17):4764-74. doi: 10.1158/1078-0432.CCR-12-0571. Epub 2012 Jul 2. Clin Cancer Res. 2012. PMID: 22753585 Clinical Trial. - MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D, Pettengell R. Alrifai D, et al. Expert Opin Investig Drugs. 2014 Dec;23(12):1731-6. doi: 10.1517/13543784.2014.972501. Epub 2014 Oct 17. Expert Opin Investig Drugs. 2014. PMID: 25323772 Review. - The role of alisertib in treatment of peripheral T-cell lymphomas.
Gallop-Evans E. Gallop-Evans E. Future Oncol. 2015 Sep;11(18):2515-24. doi: 10.2217/fon.15.154. Epub 2015 Sep 7. Future Oncol. 2015. PMID: 26344156 Review.
Cited by
- AURKA inhibition shows promise as a therapeutic strategy for ARID1A-mutant colorectal cancer.
Qin RS, Li CT, Chen F, Luo S, Wang C, Li J, Xu S, Kang M, Hu HW. Qin RS, et al. Discov Oncol. 2024 Oct 14;15(1):556. doi: 10.1007/s12672-024-01433-y. Discov Oncol. 2024. PMID: 39402330 Free PMC article. - Differential regulation of expression of the protein kinases DYRK1A and DYRK1B in cancer cells.
Vorwerk VA, Wilms G, Babendreyer A, Becker W. Vorwerk VA, et al. Sci Rep. 2024 Oct 13;14(1):23926. doi: 10.1038/s41598-024-74190-1. Sci Rep. 2024. PMID: 39397076 Free PMC article. - Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents.
Stockwell SR, Scott DE, Fischer G, Guarino E, Rooney TPC, Feng TS, Moschetti T, Srinivasan R, Alza E, Asteian A, Dagostin C, Alcaide A, Rocaboy M, Blaszczyk B, Higueruelo A, Wang X, Rossmann M, Perrior TR, Blundell TL, Spring DR, McKenzie G, Abell C, Skidmore J, Venkitaraman AR, Hyvönen M. Stockwell SR, et al. J Med Chem. 2024 Sep 12;67(17):15521-15536. doi: 10.1021/acs.jmedchem.4c01165. Epub 2024 Aug 27. J Med Chem. 2024. PMID: 39190548 Free PMC article. - Development and therapeutic evaluation of 5D3(CC-MLN8237)3.2 antibody-theranostic conjugates for PSMA-positive prostate cancer therapy.
Liatsou I, Assefa B, Liyanage W, Surasinghe S, Nováková Z, Bařinka C, Gabrielson K, Raman V, Artemov D, Hapuarachchige S. Liatsou I, et al. Front Pharmacol. 2024 May 1;15:1385598. doi: 10.3389/fphar.2024.1385598. eCollection 2024. Front Pharmacol. 2024. PMID: 38751786 Free PMC article. - Centrosomes and associated proteins in pathogenesis and treatment of breast cancer.
Athwal H, Kochiyanil A, Bhat V, Allan AL, Parsyan A. Athwal H, et al. Front Oncol. 2024 Mar 28;14:1370565. doi: 10.3389/fonc.2024.1370565. eCollection 2024. Front Oncol. 2024. PMID: 38606093 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources